Mesenchymal tumor-induced Fanconi syndrome: A novel classification of Fanconi syndrome.

Menghua Yuan, Baoping Wang, Hongzhi Li, Jin Cui, Kunling Wang, Fangqiu Zheng, Zhongshu Ma, Qing He, Ming Liu

Journal: Medicine 2025;104(39):e44845

PMID: 41029054

Abstract

RATIONALE

Fanconi syndrome (FS) caused by mesenchymal tumors is rarely reported, and these tumors are usually small and difficult to detect. However, if found and removed, the FS can be cured.

PATIENT CONCERNS

Five patients were included in this study, and their clinical features, treatments, and prognoses of tumor-induced FS were reviewed and summarized.

DIAGNOSES

Mesenchymal tumor-induced FS was diagnosed based on laboratory, imaging, and pathological examinations.

INTERVENTIONS

We performed tumor resection surgery and administered a symptomatic treatment regimen that included neutral phosphorus solution, calcitriol, calcium, and potassium supplementation, and acidosis correction.

OUTCOMES

Two patients were cured, while 3 other patients showed transient symptomatic improvement postoperatively but still required symptomatic treatment due to tumor recurrence.

LESSONS

Our case report and literature review demonstrate that mesenchymal tumors should be included in the spectrum of disorders associated with FS and that FS may represent end-stage tumor-induced osteomalacia (TIO) in certain individuals. The diagnosis of FS requires consideration of tumor-induced causes, with early detection and complete resection being crucial for a cure.

Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.

Address: Department of Endocrinology, General HospitalTianjin Medical University General Hospital, Tianjin, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.